Posted by Michael Wonder on 03 Mar 2025
Avobis Bio receives FDA fast track designation for AVB-114 implantable cell therapy for Crohn's perianal fistulas
27 February 2025 - Only implantable cell therapy for Crohn's perianal fistulas with FDA IND clearance and fast track designation.
Avobis announced today that the US FDA has granted fast track designation for AVB-114, the Company's lead therapeutic candidate for Crohn's perianal fistulas.
